TY  - BOOK
AU  - Waechter,Randall
TI  - The economics of diseases and cures /Randall Waechter, PhD, Associate Director of Research, Assistant Dean School of Graduate Studies, and Associate Professor School of Medicine, St. George's University, West Indies, editor
T2  - Economic Issues, Problems and Perspectives Ser
SN  - 9781536196146
AV  - R728 .E266 2021
KW  - Medical economics
KW  - Electronic Books
N1  - 2; Intro --; Contents --; Foreword --; Acknowledgments --; List of Acronyms --; Section A. Background and Measures --; Chapter 1 --; The Economics of Diseases and Cures --; Different Levels of Cures: Functional vs. Definitive --; Measuring the Economic Impact of Cures: Cost Strategy vs. Cures Strategy --; The Diffusion of Cures --; The Value of Case Studies --; References --; Chapter 2 --; Tools and Assumptions --; Data Sources --; Timelines --; Disease Categorization --; Cure Categorization --; Measures used to Assess the Value of Cures --; Years of Potential Life Lost (YPLL) --; Quality-Adjusted Life Years (QALY); Disability-Adjusted Life Years (DALY) --; Cure Impact --; Calculation Assumptions --; References --; Section B. Infectious Diseases --; Chapter 3 --; Acquired Immunodeficiency Syndrome (AIDS/HIV) --; Disease Category --; Disease Identification, Description, and Diagnostic Criteria --; Disease Etiology (Cause) --; Current Prevalence/Incidence --; Estimated Undiagnosed and At-Risk --; Disease Impact --; Years of Potential Life Lost (YPLL) --; Disease Impact --; Disability Adjusted Life Years (DALY) --; History of the Disease and Breakthroughs --; Current Cure Status --; Future Cure Obstacles; Research Development and Treatment Costs --; HIV Cures: Anti-Retroviral Therapy (ART) --; Cure Category --; Cure Identification/Description --; Cure History --; Cure Science: Breakthroughs/Obstacles --; Cure Science: Future Obstacles --; Number of Patients Currently Being Treatment --; Number of Patients Requiring Treatment --; Impact of Treatment on Years of Potential Life Lost (YPLL) --; Impact of Treatment on Disability-Adjusted Life Years (DALY/QALY) --; Cost of Treatment Using ART per Patient --; Cost of Lifetime Treatment Using ART --; Economic Impact --; Value of Life Added --; HIV Cures --; Vaccination; Cure Category --; Cure History --; Cure Science/Cure Obstacles --; Phase I Trials --; Phase II Trials --; Phase III Trials --; References --; Chapter 4 --; Influenza --; Disease Category --; Disease Description, Diagnosis, and Background --; Disease Etiology (Cause) --; Current Prevalence/Incidence --; Estimated Undiagnosed/At-Risk --; Disease Impact --; Years of Potential Life Lost (YPLL) --; Disease Impact --; Disability Adjusted Life Years (DALY) --; History of the Disease and Breakthroughs --; Current Cure Status --; Research, Development and Treatment Costs --; Influenza Cures: Vaccinations --; Cure Category; Cure Identification/Description --; Cure History --; Cure Science: Breakthroughs/Obstacles --; Cure Science/Future Cure Obstacles and Targets --; Number of Patients Currently Being Treated --; Number of People Requiring Treatment --; Impact of Treatment on Years of Potential Life Lost (YPLL) --; Impact of Treatment on Disability-adjusted Life Years (DALY/QALY) --; Average Annual Total/Lifetime Cost of Vaccinations --; Economic Impact --; Value of Life Added --; Economic Impact --; Value of Reduction in DALYs/Increase in QALYs --; Influenza Cures: Antivirals --; Cure Category --; Cure Identification/Description; 2; b
N2  - "This book examines the process of cure discovery and the economic impact of cures across varying diseases. It is the first time anyone has attempted to examine the [economic] returns across a wide spectrum of disease categories, using a common frame of reference"--
UR  - httpss://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=2913941&site=eds-live&custid=s3260518
ER  -